Bone metastases from solid tumours - denosumab: appraisal consultation document

The Department of Health asked the National Institute for Health and Clinical Excellence (NICE) to produce guidance on using denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours in the NHS in England and Wales. The Appraisal Committee has considered the evidence submitted and the views of non-manufacturer consultees and commentators, and clinical specialists and patient experts. This document has been prepared for consultation with the consultees. It summarises the evidence and views that have been considered, and sets out the draft recommendations made by the Committee. NICE invites comments from the consultees and commentators for this appraisal (see appendix B) and the public. This document should be read along with the evidence base (the evaluation report), which is available from www.nice.org.uk The Appraisal Committee is interested in receiving comments on the following: Has all of the relevant evidence been taken into account? Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence? Are the provisional recommendations sound and a suitable basis for guidance to the NHS? Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?